Key Points {#d30e225}
==========

The pharmacokinetics of a single oral dose of two polymorphic forms (Form A versus Form C) of ponesimod in capsules and a tablet formulation (Form C) were compared.Comparison between the two polymorphic forms and comparison between the capsule and tablet formulations did not reveal relevant differences in pharmacokinetic and safety properties.Capsules can be substituted with tablets, from which ponesimod is absorbed slightly more rapidly.

Introduction {#Sec1}
============

Sphingosine-1-phosphate (S1P) is a phospholipid displaying a wide range of physiological roles \[[@CR1]--[@CR3]\]. S1P effects are mediated by the activation of five G-protein-coupled receptors, S1P~1~ to S1P~5~. Among them, the S1P~1~ receptors, which are expressed in many cell types (e.g., lymphocytes, cardiomyocytes, and endothelial cells), induce *G*~αi~ protein-mediated signaling and play a role in the immune and cardiovascular systems \[[@CR4]\]. Recent studies have revealed that functional antagonism of the S1P~1~ receptor leads to inhibition of the egress of lymphocytes from secondary lymphoid organs and a low lymphocyte count in peripheral blood \[[@CR5]\].

Ponesimod (ACT-128800) is a potent, orally active, selective, reversible S1P~1~ receptor modulator \[[@CR6]\] currently in clinical development for the treatment of autoimmune diseases and has successfully reached its study end points in recent phase II trials in patients with chronic plaque psoriasis \[[@CR7]\] or relapsing--remitting multiple sclerosis \[[@CR8]\]. Single- and multiple-dose administration of ponesimod results in a dose-dependent decrease in circulating lymphocytes in healthy subjects and is associated with heart rate reduction, a delay in atrioventricular conduction, and pulmonary effects \[[@CR9]--[@CR13]\].

The maximum plasma concentration (*C*~max~) is achieved approximately 2--4 h after dosing (*t*~max~), and the terminal half-life (*t*~½~) is approximately 32 h. Steady-state conditions are attained within 4--5 days when ponesimod is administered once daily at any given dose. Increases in *C*~max~ are dose proportional, while increases in the area under the curve (AUC) are slightly greater than dose proportional \[[@CR9]--[@CR11]\]. A previous study \[[@CR9]\] revealed low variability in pharmacokinetic parameters (inter-subject variability \<36 %). Previous clinical trials were performed with polymorph Form A (a hydrated crystalline form) of ponesimod capsules. During the development of the drug, solid-state investigations revealed the existence of distinct polymorphic forms of ponesimod. Form C (an anhydrous polymorphic form)---the thermodynamically most stable form at room temperature so far known---was identified. Moreover, a tablet formulation of Form C with a smaller size, compared with the capsules, was developed.

The aim of this study was to compare the two polymorphic forms (Form A and Form C in capsules), as well as the capsule and tablet formulations of Form C of ponesimod, in terms of their pharmacokinetics, safety, and tolerability, in order to bridge the results obtained in early clinical studies using capsules of Form A with those of later studies.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Healthy male and female subjects aged between 18 and 65 years were included in this study. The health of the subjects was assessed at the screening visit, which included recording of the medical history, medications taken during the 3 months preceding the screening visit, a physical examination, measurement of body weight and height, clinical laboratory tests, recording of vital signs, and a standard electrocardiogram (ECG). Because of the teratogenic potential of ponesimod, women of childbearing potential were required to use two reliable and protocol-approved methods of contraception from screening until 2 months after the last study drug intake. At screening, subjects had to have a PR interval of \<200 ms, a heart rate of \>55 beats per minute (bpm), and a total lymphocyte count of \>1000 lymphocytes/µL. Written informed consent was obtained from each individual participating in the study prior to any study procedure and after adequate explanation of the aims, methods, objectives, and potential hazards of the studies. These studies were conducted at different centers and at different times. The Comité de Protection des Personnes (Paris, France) approved the protocol of Study 1, and the Aspire Institutional Review Board (La Mesa, CA, USA) approved the protocol of Study 2. These studies were performed according to good clinical practice and in accordance with the principles of the Declaration of Helsinki.

Study Design {#Sec4}
------------

This work was performed at two centers, one in France for the comparison of polymorphic Form A and Form C in capsules (Study 1) and one in the USA for the comparison between capsules and tablets of Form C (Study 2). Each study was a single-center, randomized, open-label, two-period, two-treatment, crossover, biocomparison study. A total of 26 subjects (12 healthy male subjects in Study 1: age 31.3 \[±12.8\] years, body weight 75.4 \[±11.3\] kg; 14 healthy male and female subjects \[ratio 1:1\] in Study 2: age 31.1 \[±14.9\] years, body weight 69.0 \[±14.5\] kg) were enrolled, and all subjects received active treatment. A power of 80 % was estimated with a sample size of 12 subjects (in Study 1) and 14 subjects (in Study 2), based on an intra-subject coefficient of variation of the tablet formulation of \~12 % observed in previous clinical trials of ponesimod. The treatment consisted of two treatment periods of a single dose of ponesimod 20 mg as one Form A or Form C capsule (in Study 1) or two treatment periods of a single dose of ponesimod 40 mg either as one capsule or one tablet (in Study 2). These doses have been used in phase II trials \[[@CR7], [@CR8]\]. All treatments were administered in the morning with approximately 240 mL of water, and the two treatment periods were separated by a wash-out period of 8--15 days in Study 1 and 14--15 days in Study 2. The subjects remained fasted from at least 10 h prior to drug intake until 4 h afterward. The subjects remained in the clinic from day −1 (i.e., the day prior to study drug administration) until day 2, 24 h after study drug administration, and they could then be discharged if this was allowed on the basis of their medical condition at the end of each treatment period. An end-of-study visit comprising the same examinations as those performed at the screening visit was conducted 6 days or 22 (+2) days after the last study drug administration in Study 1 and Study 2, respectively.

Safety and Tolerability Assessments {#Sec5}
-----------------------------------

Safety and tolerability were evaluated by monitoring of adverse events and vital signs (supine blood pressure and heart rate), a cardiodynamic assessment (a 12-lead ECG recording), pulmonary function tests, clinical laboratory tests, and physical and neurological examinations.

Vital signs were recorded from subjects in the supine position after they had rested for at least a 5-min period pre-dose and 1, 2.5, 4, 10, 24, 48, and 144 h after study drug administration in both Study 1 and Study 2. In Study 1, vital signs were, in addition, recorded 0.5, 1.5, 6, 36, 72, 96, and 120 h after study drug administration. A standard 12-lead ECG was recorded at rest in the supine position pre-dose and 1, 2.5, 4, 10, 24, 48, and 144 h after study drug administration in both studies. Clinical laboratory tests and a physical examination were done prior to study drug administration and during the end-of-study visit.

Pharmacodynamic Assessments {#Sec6}
---------------------------

A lymphocyte count was only performed pre-dose and 144 h after ponesimod administration in Study 2. Two additional assessments (24 and 48 h after study drug administration) were performed in Study 1.

Pharmacokinetic Assessments and Analysis {#Sec7}
----------------------------------------

Blood samples of about 3 mL were collected in ethylenediaminetetraacetic acid (EDTA) tubes just before study drug administration and 0.5, 1, 1.5, 2.5, 4, 6, 10, 16, 24, 36, 48, 72, 96, 120, and 144 h after study drug administration in both Study 1 and Study 2. After centrifugation, plasma was transferred into a labeled polypropylene tube and stored at −21 °C (±5 °C) pending analysis. Plasma concentrations of ponesimod were determined using a validated liquid chromatography--tandem mass spectrometry (LC--MS/MS) assay with a lower limit of quantification of 1 ng/mL \[[@CR9]\]. Analysis of quality-control samples of all runs showed that the inter-day coefficients of variation were \<12.2 %, whereas the average intra-day inaccuracy was in the range of −6.0 to 3.3 %. Noncompartmental pharmacokinetic analyses were performed using Professional WinNonlin 6.1 software (Pharsight Corp., Mountain View, CA, USA). The variables *C*~max~ and *t*~max~ were directly read from the plasma concentration--time profiles, AUC from time zero to the time of the last measurable concentration (AUC~0--t~) was calculated using the trapezoidal method \[[@CR14]\], and *t*~½~ was calculated as ln 2/*λz*, where *λz* is the terminal elimination rate constant estimated by log-linear regression analysis. Pharmacokinetic variables were analyzed descriptively, providing geometric means and 95 % confidence intervals (CIs) for *C*~max~, AUC from time zero to infinity (AUC~0--inf~), AUC~0--t~ (i.e., AUC from time zero to 144 h \[AUC~0--144h~\]), and *t*~½~. For *t*~max~, the median with minimum and maximum values were calculated and reported.

Statistical Analysis {#Sec8}
--------------------

Safety and tolerability data were analyzed descriptively. Bioequivalence was explored, and the geometric mean ratios of AUC and *C*~max~ of Form C/Form A and tablet/capsule, as well as their 90 % CIs, were derived from mixed-effect models with treatment, sequence, and period as fixed effects and subjects as random effects, and by a linear model with treatment and subjects as fixed effects. Differences in *t*~max~ were explored using the nonparametric Wilcoxon signed-rank test.

SAS^®^ software versions 8.2 and 9.1 (SAS Institute, Cary, NC, USA) were used for the statistical analysis and the reporting of safety and tolerability data. For the pharmacokinetics, the statistical package R (R Foundation for Statistical Computing Version 2.6.1, lme function) was used. Cardiodynamic and pharmacodynamic data are expressed as mean ± standard deviation (SD). The Student's *t* test was used to analyze the effects of ponesimod on the heart rate and blood pressure. Differences were considered to be statistically significant at *p* \< 0.05.

Results {#Sec9}
=======

Pharmacokinetics {#Sec10}
----------------

In Study 1, the plasma concentration--time profiles of ponesimod were characterized by a median *t*~max~ of 4 h for both polymorphic forms in capsules (Fig. [1](#Fig1){ref-type="fig"}a; Table [1](#Tab1){ref-type="table"}). Table [1](#Tab1){ref-type="table"} reveals that following ponesimod 20 mg, the observed total exposure, *C*~max~, and *t*~½~ were similar with Form A and Form C. When bioequivalence was explored by mixed-effect and linear models, the geometric mean ratios (and 90 % CIs) of *C*~max~ and AUC for Form C versus Form A capsules were all within the 0.80--1.25 bioequivalence interval (Fig. [2](#Fig2){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}).Fig. 1Arithmetic mean (with standard deviation) plasma concentration--time profiles of ponesimod (*left graphs* from 0 to 144 h \[with linear scales and semi-logarithmic scales shown as *insets*\]; *right graphs* from 0 to 8 h) in healthy subjects after a single dose of **a** 20 mg as a Form A or Form C capsule (*n* = 12) or **b** 40 mg as a Form C capsule or tablet (*n* = 14)Table 1Comparison of pharmacokinetic parameters of the two polymorphic forms (Study 1) and the tablet versus capsule formulations (Study 2)*NC* ~max~ (ng/mL)*t* ~max~ (h)^a^AUC~0--t~ (ng·h/mL)AUC~0--inf~ (ng·h/mL)*t* ~½~ (h)Study 1 (20 mg) Form A1295.0 (82.0--110)4.0 (2.5--6.0)3006 (2718--3325)3091 (2806--3404)26.3 (23.6--29.4) Form C1289.4 (70.7--113)4.0 (2.5--10.0)3064 (2649--3544)3150 (2725--3641)27.4 (25.1--29.9) Form C versus Form A^b^120.94 (0.81--1.10)NC1.02 (0.93--1.12)1.02 (0.93--1.12)NCStudy 2 (40 mg) Capsule14201 (160--251)5.0 (2.5--16.0)7542 (6122--9290)7912 (6391--9795)31.2 (26.4--36.9) Tablet14255 (212--307)4.0 (3.9--5.3)8146 (6641--9991)8431 (6821--10,421)28.0 (24.8--31.7) Tablet versus capsule^b^141.27 (1.15--1.40)NC1.08 (0.96--1.22)1.07 (0.95--1.19)0.90 (0.77--1.05)The data are expressed as geometric mean (95 % confidence interval), except where indicated otherwise*AUC* ~*0--inf*~ area under the curve from time zero to infinity, *AUC* ~*0--t*~ area under the curve from time zero to the time of the last measurable concentration, *C* ~*max*~ maximum plasma concentration, *NC* not calculated, *t* ~*½*~ terminal half-life, *t* ~*max*~ time to maximum plasma concentration^a^The data are expressed as median (range)^b^The data are expressed as geometric mean ratio (90 % confidence interval)Fig. 2Geometric mean ratios (with 90 % confidence intervals) derived from mixed-effect models of the area under the curve from time zero to the time of the last measurable concentration (AUC~0--t~), the area under the curve from time zero to infinity (AUC~0--inf~), and the maximum plasma concentration (*C* ~max~) in Study 1 (comparison of the two polymorphic Forms C and A; *n* = 12) and in Study 2 (comparison of the tablet and capsule formulations; *n* = 14). The *dotted lines* represent the lower and upper bounds of the bioequivalence interval (0.80--1.25)

In Study 2, subjects received ponesimod 40 mg as either a tablet or a capsule of Form C. When both formulations were compared, total exposure and *t*~½~ were similar (Table [1](#Tab1){ref-type="table"}). *C*~max~ was slightly higher and reached earlier with the tablet than with the capsule (Fig. [1](#Fig1){ref-type="fig"}b; Table [1](#Tab1){ref-type="table"}), indicating more rapid absorption of ponesimod when administered in the tablet formulation. The 90 % CIs of the estimated geometric mean ratios of AUC~0--t~ (AUC~0--144h~) and AUC~0--inf~ were contained within the 0.80--1.25 bioequivalence interval. The estimated geometric mean ratio for *C*~max~ was 27 % higher (i.e., ratio 1.27) with the tablet than with the capsule formulation (90 % CI 1.15--1.40), and *t*~½~ tended to be slightly shorter with the tablet formulation (ratio 0.90, 90 % CI 0.77--1.05) (Fig. [2](#Fig2){ref-type="fig"}).

In Study 2, both male and female subjects (ratio 1:1) were enrolled. The observed *C*~max~ was greater in female subjects (geometric means \[95 % CIs\] 251.4 \[176.6--357.8\] ng/mL and 326.8 \[272.7--391.7\] ng/mL for capsules and tablets, respectively) than in male subjects (160.1 \[127.2--201.7\] ng/mL and 199.4 \[165.4--240.0\] ng/mL for capsules and tablets, respectively). Moreover, exposure to ponesimod (AUC~0--inf~) was greater in female subjects (9841 \[7292--13,280\] ng·h/mL and 10,864 \[8826--13,372\] ng·h/mL for capsules and tablets, respectively) than in male subjects (6361 \[4896--8264\] ng·h/mL and 6543 \[4947--8654\] ng·h/mL for capsules and tablets, respectively), and *t*~½~ was slightly longer in female subjects (37.1 \[27.8--49.5\] h and 31.2 \[24.6--39.5\] h for capsules and tablets, respectively) than in male subjects (26.3 \[23.2--29.7\] h and 25.2 \[23.3--27.3\] h for capsules and tablets, respectively).

Safety and Tolerability {#Sec11}
-----------------------

No serious or severe adverse events occurred during these two studies. There was no marked difference in the nature, severity, and incidence of adverse events reported for the different formulations in Study 1 (Form A and Form C capsules) and Study 2 (Form C capsule and tablet) (Table [2](#Tab2){ref-type="table"}). All reported adverse events were of mild to moderate intensity, were considered by the investigators to be related to the study drug, and were reported as being resolved by the end of the studies. In both studies, the most frequently observed adverse events were headache, dizziness, nausea, and sinus bradycardia (defined as a heart rate below 40 bpm), and three subjects (one in Study 1 and two in Study 2) displayed an event of first-degree atrioventricular block (defined as a PR interval above 200 ms). When comparing Study 1 and Study 2 (Table [2](#Tab2){ref-type="table"}), the incidence of adverse events (i.e., the number of subjects with at least one adverse event) was higher following administration of ponesimod 40 mg (85.7 %) than following ponesimod 20 mg (33.3 %).Table 2Treatment-emergent adverse events (AEs) in Study 1 and Study 2Study 1 (20 mg)Study 2 (40 mg)Form AForm CCapsuleTabletTreatment Number of subjects dosed12121414 Number of subjects with at least one AE (%)4 (33.3)4 (33.3)12 (85.7)12 (85.7) Total number of AEs654043Number of subjects reporting an event (%) Headache2 (16.7)1 (8.3)4 (28.6)6 (42.9) Dizziness----9 (64.3)7 (50.0) Sinus bradycardia2 (16.7)1 (8.3)6 (42.9)6 (42.9) First-degree atrioventricular block1 (8.3)1 (8.3)1 (7.1)1 (7.1) Nausea1 (8.3)1 (8.3)2 (14.3)2 (14.3) Vomiting--1 (8.3)--1 (7.1)

In Study 1, maximum heart rate changes of (mean ± SD) −20.2 ± 6.0 bpm (*t* = 9.2, *p* \< 0.001) and −18.8 ± 5.6 bpm (*t* = 10.7, *p* \< 0.001) 2.5 h after administration of Form A and Form C, respectively, were observed (Fig. [3](#Fig3){ref-type="fig"}a). There was no relevant difference between the two polymorphic forms of ponesimod (*t* = 0.6, *p* = 0.6).Fig. 3Arithmetic mean (with standard deviation) heart rates from 0 to 144 h after administration of ponesimod at a dose of **a** 20 mg (Study 1; *n* = 12) or **b** 40 mg (Study 2; *n* = 14) in healthy subjects. The *insets* show the arithmetic mean heart rates (with standard deviations) from 0 to 10 h. *bpm* beats per minute

In Study 2, the maximum heart rate changes were (mean ± SD) −15.6 ± 10.6 bpm (*t* = 4.9, *p* \< 0.0001) and −16.2 ± 6.4 bpm (*t* = 5.0, *p* \< 0.0001) 2.5 h after administration of the capsule and tablet formulations, respectively (Fig. [3](#Fig3){ref-type="fig"}b). There was no relevant difference between the capsule and tablet formulations of Form C (*t* = 0.2, *p* = 0.9) (Fig. [3](#Fig3){ref-type="fig"}b).

A reduction in blood pressure, compared with baseline, following administration of both polymorphic forms of ponesimod (20 mg) was observed. However, no relevant differences were observed in the decrease in systolic and diastolic blood pressure between Form A (systolic: −7 ± 11 mmHg; diastolic: −10 ± 7 mmHg) and Form C (systolic: −6 ± 14 mmHg, *t* = 0.2, *p* = 0.8; diastolic: −8 ± 5 mmHg, *t* = 0.8, *p* = 0.4). In Study 2, both the capsule (systolic: −7 ± 9 mmHg; diastolic: −9 ± 8 mmHg) and the tablet (systolic: −6 ± 6 mmHg, *t* = 0.4, *p* = 0.7; diastolic: −7 ± 11 mmHg, *t* = 0.7, *p* = 0.5) formulations triggered similar decreases in blood pressure. The maximum decrease in blood pressure was observed 2.5 h after ponesimod administration in both Study 1 and Study 2.

In both studies, administration of ponesimod 20 or 40 mg did not alter other safety parameters, such as ECG variables (including the QTcB and QTcF intervals) and body weight. There were no marked differences regarding the number of ECG abnormalities in Study 1 (three ECG abnormalities were observed with each polymorphic form) or Study 2 (16 and 20 abnormalities were observed with the capsule and tablet, respectively). Thus, the frequency of abnormalities was higher following administration of ponesimod 40 mg than following ponesimod 20 mg.

As expected, a single administration of ponesimod 20 mg (mean ± SD decreases in the number of lymphocytes: −1.05 ± 0.50 × 10^9^ cells/L and −0.95 ± 0.47 × 10^9^ cells/L for Form A and Form C, respectively) or 40 mg (−0.30 ± 0.51 × 10^9^ cells/L and −0.23 ± 0.27 × 10^9^ cells/L for the capsule and tablet, respectively) led to a reduction in the lymphocyte count (not shown). This effect was not considered to be an adverse event, as it is an anticipated pharmacodynamic effect of the drug.

Discussion {#Sec12}
==========

The aim of the present study was to compare two polymorphic capsule forms, as well as comparing tablet and capsule formulations (of the same polymorphic form) of ponesimod, a potent S1P~1~ modulator.

The capsule and tablet formulations of ponesimod have similar concentration--time profiles and exposure, as well as *t*~½~ values, though absorption of ponesimod from the tablet formulation was slightly more rapid, with a higher *C*~max~ than that seen with the capsule formulation. The observed safety profile was comparable between the different formulations. Previous clinical studies were performed with ponesimod polymorphic Form A. This form is a crystalline solid obtained by rapid precipitation, whereas another formulation obtained by slow crystallization has been developed. This Form C is thermodynamically more stable than Form A. In addition, the slow crystallization of Form C in the final step of the synthesis is easier to control and more reproducible, especially on a large manufacturing scale, than the rapid precipitation that yields Form A. In addition, a tablet formulation has been developed, which is preferred to the capsule formulation, since the tablets are smaller and easier to swallow, which may improve patient compliance. It is worth noting that difficulties in swallowing are relatively frequent in patients with multiple sclerosis \[[@CR15]\]. More importantly, tablets are generally more stable than capsules. In the present work, we have shown bioequivalence between the two polymorphic forms of ponesimod, and we observed slightly more rapid absorption of ponesimod when it was administered as tablet formulation. Therefore, ponesimod capsules can be substituted with tablets without any dose adjustment.

Between Study 1 and Study 2, the increases in *C*~max~ were dose proportional and the increases in AUC were slightly greater than dose proportional, which is in line with the findings of previous clinical studies performed with ponesimod \[[@CR8]--[@CR11]\]. Whereas similar exposure in male and female subjects has been seen previously \[[@CR10]\], the findings of a recent study \[[@CR11]\] are in good agreement with the greater exposure in female subjects that was observed in the present work. This finding could be related to differences in body weight, requiring dose adjustment \[[@CR16], [@CR17]\].

In terms of safety and tolerability, a similar incidence and nature of adverse events was observed in Study 1 and Study 2. No new findings were observed, in comparison with previous studies \[[@CR7]--[@CR13]\]. The incidence of adverse events and the percentage of subjects displaying adverse events were dose dependent. In current phase II studies, an up-titration scheme (a first dose of 10 mg) is applied in patients to improve the safety and tolerability of ponesimod treatment \[[@CR7], [@CR8]\]. The lymphocyte nadir (maximum observed decrease) was higher following administration of ponesimod 20 mg than following 40 mg. This might have been related to the timing of the assessments. Indeed, in Study 2, the lymphocyte count was assessed pre-dose and 144 h after ponesimod administration. In Study 1, additional assessments were performed daily.

In good agreement with previous studies, we observed transient significant reductions in the heart rate and blood pressure following administration of ponesimod, which were induced by the activation of S1P~1~ \[[@CR18]\]. The maximum decrease was observed 2.5 h after ponesimod administration, and the heart rate returned to baseline within 10 h, as previously observed \[[@CR9]--[@CR11]\]. When comparing Study 1 and Study 2, no clear dose-dependent effect was observed. This was also the case in a previous study, in which the decrease in the heart rate was similar in the 20 and 50 mg dose groups \[[@CR9]\]. While comparison across studies has limitations, we may assume that the effect on the heart rate reaches a plateau with ponesimod 20 mg. This reduction in the heart rate following ponesimod administration is explained by the internalization of the S1P~1~ receptors and their desensitization. This effect has been well characterized for S1P modulators \[[@CR18]--[@CR20]\].

Conclusion {#Sec13}
==========

The two polymorphic forms of ponesimod and the tablet and capsule formulations were similar in terms of their pharmacokinetics, except for more rapid absorption of the tablet formulation than the capsule formulation. At the same dose, the strength, safety, and tolerability were similar. Therefore, Form A can be substituted with Form C, and capsules can be substituted with tablets.
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